NCT00177190

In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)

In Vitro Evaluation of Immune Responses in CTCL

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 8 (actual)
• Sponsor: University of Pittsburgh · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an in vitro evaluation of cutaneous T-cell lymphoma using patients' blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/CD 8 cells.

Detailed description

This is an in vitro evaluation of cutaneous T-cell lymphoma using patients blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/ CD 8 cells with the following objectives: * Objective I: Evaluate the feasibility of the preparation of dendritic cells (DCs), CD8 and Sezary cells (all CD4 positive) in vitro, obtained from the buffy coats or a skin biopsy from an area with tumor involvement of subjects with cutaneous t-cell lymphoma (CTCL) and Sezary syndrome (leukemic stage of CTCL) undergoing an approved FDA therapy, extracorporeal photopheresis (ECP). * Objective II: Evaluate antigen loading of the DCs. * Objective III: Test the functional capacities of the DCs derived from CTCL subjects to overcome immune tolerance to the tumor cells ex-vivo, by using modified Elispot assay in conjunction with Granzyme B Elispot assay as a measurement of cytotoxicity.

Conditions

• Cutaneous T-cell Lymphoma
• Sezary Syndrome
• Mycosis Fungoides

Timeline

• Start date: 2002-06-01
• Primary completion: 2005-01-01
• Completion: 2006-01-01
• First posted: 2005-09-15
• Last updated: 2014-05-28

Locations

1 site across 1 country: United States